We kick off the new year with host Stuart Fieldhouse talking to Gary Robinson, a partner at Baillie Gifford and the manager of the Baillie Gifford US Growth Trust [LON;USA], a FTSE 250 constituent. It seems like a timely discussion with so much focus on the US market at the moment. and with hedge fund Saba Capital seeking to take control of the trust's board.

On the podcast we chat about the investment trust's strategy and especially its exposure to unlisted companies. We look at how the trust optimises its exposure to the US tech sector and whether the Mag 7 stocks are distracting tech investors from other opportunities. Gary also gives us his views on how to spot the next big technology success story.

It's not all tech though: we also had time to look at the US healthcare sector and of course the likely impact of Donald Trump on the US stock market.

Listeners should be aware that the podcast was recorded prior to Saba Capital's announcement on 18 December in which it said it would seek governance changes at seven listed trusts.

For more great investing ideas, news and insight, sign up to our FREE newsletter at www.thearmchairtrader.com/newsletter/

For stock tips and deeper company analysis get a free trial of Armchair Trader Plus+ at www.thearmchairtrader.com/register

00:00 Intro to the Baillie Gifford US Growth Trust

03:18 Private companies in the portfolio

06:21 Why large tech companies decide not to IPO

08:12 The Mag7 stocks

10:40 Findind the next Amazon or Nvidia

14:14 Corporate culture and visionary management teams

16:33 Healthcare sector holdings

19:04 Will the new presidency be good for US growth stocks?

21:38 Gary's two favourite stocks